Breaking Down Xiangxue Pharmaceutical Co.,Ltd. Financial Health: Key Insights for Investors

Xiangxue Pharmaceutical's recent financials paint a stark picture for investors: 2024 revenue fell to CNY 1.86 billion (down 19.16% y/y) and Q1 2025 revenue was just CNY 421 million (down 26% y/y), while the company reported a 2024 net loss of about CNY 861.2 million (a 120.7% increase in losses) and a Q1 2025 loss of CNY 87.73 million; liquidity and solvency metrics are strained with total debt near CNY 1.96 billion versus only CNY 131.7 million in cash, a current ratio of 0.28, total assets of CNY 7.36 billion and liabilities of CNY 6.05 billion, all amid regulatory headwinds (an CSRC notice and trading restrictions since March 25, 2025) and a market capitalization of CNY 5.53 billion as of July 1, 2025-read on for a detailed breakdown of revenue drivers, profitability erosion, leverage risks, cash-flow dynamics, valuation multiples (P/E -6.44; P/S 3.24; P/B 5.84; EV/Revenue 4.79) and the strategic opportunities tied to partnerships and tech initiatives that could reshape the company's outlook

Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) - Revenue Analysis

• 2024 full-year revenue: CNY 1.86 billion (-19.16% YoY vs. CNY 2.30 billion in 2023)
• Q1 2025 revenue: CNY 421 million (-26% YoY vs. CNY 568.86 million in Q1 2024)
• Estimated 2024 operating revenue range: CNY 1.613 billion - CNY 2.013 billion
• Primary headwinds: intensified competition, higher inventory turnover pressure, liquidity crisis

• Segment impact: Chinese Patent Medicine sales down → lower operating income and declining gross margins
• Operational effects: higher inventory turnover pressure, potential discounting, slower cash conversion
• Financial effects: liquidity crisis limiting working capital and commercial investments

Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) Profitability Metrics

Xiangxue Pharmaceutical's recent performance shows material and persistent profitability pressure across annual and trailing measures. Key headline figures illustrate widening losses, negative margins and weak returns on capital.

• 2024 reported net loss: CNY 861.2 million (increase of 120.7% vs 2023 loss of CNY 388.96 million).
• Projected 2024 net loss range: CNY 599.6 million to CNY 862.4 million.
• Q1 2025 net loss: CNY 87.73 million vs Q1 2024 loss of CNY 35.66 million.
• TTM net profit margin: -46.19%.
• Operating margin (2024): -0.74%.
• Return on assets (TTM): -2.19%; Return on equity (TTM): -50.10%.

These metrics indicate continued operating losses and negative profitability ratios, with equity returns particularly strained by net losses and possible equity dilution or impairments.

• Implications for investors:
  • Negative TTM margin (-46.19%) signals severe earnings weakness relative to revenue.
  • ROE of -50.10% suggests shareholder equity is being eroded rapidly by losses.
  • Operating margin near zero (-0.74%) implies that core operations are not covering costs effectively.

Further context on business model, ownership and history can be found here: Xiangxue Pharmaceutical Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) - Debt vs. Equity Structure

• Total debt: CNY 1.96 billion (short- and long-term borrowings combined).
• Cash and equivalents: CNY 131.7 million - a small liquidity buffer relative to debt.
• Total assets: CNY 7.36 billion; total liabilities: CNY 6.05 billion.
• Debt-to-equity ratio: 201.77% - more than double shareholder equity, indicating high leverage.
• Financial costs (2024): ≈ CNY 230 million - a significant drag contributing to net losses.
• Corporate governance / market status flags: shares under special trading restrictions since March 25, 2025 (stock marked 'ST Xiangxue'); one-day trading suspension on March 24, 2025 due to disclosure of false records in the 2019 annual report.

• Liquidity strain: cash covers only a small fraction (~6.7%) of total debt (131.7M / 1,960M ≈ 6.72%).
• High leverage: debt-to-equity >200% raises refinancing and solvency risk, especially if operating cash flow remains weak.
• Interest burden: CNY 230M in financial costs in 2024 materially pressures net income and limits reinvestment capacity.
• Market and regulatory risk: special treatment ('ST') and prior disclosure issues increase event-driven volatility and may restrict institutional appetite.

Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) - Liquidity and Solvency

• Current ratio (as of March 31, 2025): 0.28 - well below the conventional 1.0 threshold, indicating difficulty covering current liabilities with current assets.
• Operating cash flow (full-year 2024): CNY 18.2 million - insufficient to fund capital expenditures of CNY 35.2 million in the same period.
• Net change in cash (latest quarter): CNY 34.66 million - a positive quarterly swing, but one that must be viewed in the context of minimal operating cash flow and ongoing cash burn.
• Operating cash flow generation remains minimal, raising material risk about meeting short-term obligations without external financing or asset dispositions.
• Liquidity constraints are compounded by ongoing operational losses and a significant debt burden; refinancing options may be limited under the current regulatory designation.

Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) Valuation Analysis

As of July 1, 2025, Xiangxue Pharmaceutical's market capitalization stood at CNY 5.53 billion. The headline valuation metrics point to a stressed earnings profile and market-imposed discounts driven by both operational performance and recent regulatory/trading events.

• Market capitalization: CNY 5.53 billion (as of 2025-07-01)
• Trailing P/E (TTM): -6.44 - negative earnings on a trailing basis
• Price-to-Sales (TTM): 3.24
• Price-to-Book (MRQ): 5.84
• Enterprise Value / Revenue: 4.79
• Enterprise Value / EBITDA: -136.57 - implies negative or near-zero EBITDA relative to enterprise value
• Regulatory/market events: trading suspended one day on 2025-03-24 for disclosure issues in the 2019 annual report; special trading restrictions and 'ST Xiangxue' designation effective from 2025-03-25

Key valuation implications and investor considerations include:

• Negative trailing P/E means traditional earnings-based valuation comparables are not directly applicable; reliance on revenue, book value, or forward projections is necessary.
• Price-to-Sales of 3.24 and EV/Revenue of 4.79 suggest the market still prices a premium to revenue despite losses - implying expectations of recovery or value in assets/intangibles.
• High P/B of 5.84 can indicate market optimism about intangible value or low book equity; it also raises concern about downside if asset recoverability is questioned under the 'ST' regime.
• Very large negative EV/EBITDA (-136.57) signals extremely weak operating profitability; small changes in EBITDA can swing this ratio dramatically and make it volatile and unreliable for cross-company benchmarking.
• Regulatory events (false-record disclosure, trading suspension, ST designation) materially increase investor risk - liquidity, forced selling, and governance concerns should be factored into valuation margins.

For deeper context on the company's history, ownership and business model, see: Xiangxue Pharmaceutical Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) - Risk Factors

• Regulatory action: On March 21, 2025, Xiangxue Pharmaceutical received an 'Advance Notice of Administrative Punishment' from the China Securities Regulatory Commission related to false records in the 2019 annual report.
• Market status: From March 25, 2025 the company's shares have been placed under special treatment; the stock abbreviation was changed to 'ST Xiangxue' and trading restrictions apply.
• Trading disruption: Stock trading was suspended for one day on March 24, 2025 following disclosure of the false records issue for 2019.
• Repeated listing risk: The special treatment ('ST') status increases risk of delisting if performance, compliance or reporting deficiencies are not remedied.

• Cash-flow risk: Operating cash flow remains minimal/negative (≈RMB -120m), constraining routine capex, R&D funding and debt servicing.
• Liquidity & solvency: Low current and quick ratios plus RMB 1.1bn of short-term borrowings create high rollover and default risk if credit lines tighten.
• Profitability pressure: Continued operating losses (net loss ≈RMB 480m) undermine retained earnings and restrict ability to absorb regulatory fines or remediation costs.
• Regulatory & market risk: The CSRC notice and ST designation can accelerate investor flight, reduce free float, and increase cost of capital; repeated listing-procedure scrutiny may follow.
• Reputational risk: Historical false record findings may impair commercial relationships, regulatory approvals, and access to public markets for capital raising.
• Contagion of trading restrictions: Ongoing special trading status since March 25, 2025 limits liquidity and may lead to forced sales or margin-induced volatility.

Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) - Growth Opportunities

• Strategic digital partnership: a strategic partnership agreement with 111, Inc. to develop an 'Internet + Medicine' model for China's traditional Chinese medicine (TCM) industry - enabling online distribution, prescription services and data-driven patient engagement.
• Operational discipline: management emphasizes clearer annual operational targets and a development strategy intended to reduce sensitivity to cyclic market swings (pricing pressure, raw-material volatility).
• Internal optimization & external expansion: programs to streamline manufacturing, lower SG&A per unit and accelerate geographic expansion into second- and third-tier Chinese cities and selective overseas markets.
• Technology and product innovation: exploration of embodied intelligence and humanoid-robot-related applications - both for manufacturing automation (pick-and-place, inspection) and potential patient-facing solutions in pharmacies/clinics.
• Repetition of focus for emphasis: continued alignment of strategy and annual goals to mitigate market impact and ensure predictable execution across product lines.
• Management priorities reiterated: vigorous market expansion combined with internal efficiency drives to lift margins and ROIC over time.

• Digital channel opportunity: leveraging 111, Inc. can increase direct-to-patient prescriptions and recurring revenue, potentially lifting blended gross margins by 200-400 bps over 2-3 years if adoption and logistics scale.
• Manufacturing automation: investment in embodied intelligence and robotics could lower COGS and headcount-driven SG&A by improving throughput and reducing defect rates.
• Product pipeline and differentiation: focused R&D spend on high-margin proprietary TCM formulations and revamped delivery formats (granules, patches) supports premium pricing in select categories.
• Market expansion levers: deeper penetration in lower-tier cities and selective cross-border exports can diversify revenue mix and reduce domestic policy concentration risk.
• Balance-sheet flexibility: modest leverage provides room for M&A to acquire niche brands, digital capabilities or manufacturing capacity that accelerate growth.